Subgroup | No. study | No. patients | Pooled HR (95% CI) | p | p for subgroup difference | Heterogeneity | |
---|---|---|---|---|---|---|---|
I2(%) | PQ | ||||||
Altogether | 4 | 6035 | 2.19(1.57–3.05) | < 0.001 | 0.0 | 0.94 | |
Publishing time | 0.921 | ||||||
< 2019 | 2 | 2171 | 2.22(1.37–3.60) | 0.001 | 0.0 | 0.573 | |
≥ 2019 | 2 | 3864 | 2.15(1.35–3.42) | 0.001 | 0.0 | 0.783 | |
Country | 0.875 | ||||||
China | 1 | 5788 | 2.28(1.22–4.25) | 0.009 | — | — | |
Japan | 3 | 83 | 2.15(1.45–3.19) | < 0.001 | 0.0 | 0.828 | |
Sample | 0.875 | ||||||
< 300 | 1 | 1295 | 2.15(1.45–3.19) | 0.009 | — | — | |
≥ 300 | 3 | 4740 | 1.81(1.58–2.07) | < 0.001 | 0.0 | 0.828 | |
Cutoff value | 0.921 | ||||||
< 98 | 2 | 3274 | 2.22(1.37–3.60) | 0.001 | 0.0 | 0.573 | |
≥ 98 | 2 | 2761 | 2.15(1.35–3.42) | 0.001 | 0.0 | 0.783 | |
Cancer site | 0.921 | ||||||
GC | 2 | 888 | 2.22(1.37–3.60) | 0.001 | 0.0 | 0.573 | |
CRC | 2 | 6035 | 2.15(1.35–3.42) | 0.001 | 0.0 | 0.783 |